Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.